ZIM
JUNO

Zacks Investment Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Zacks Investment Management’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-13,604
Closed -$407K – 707
2017
Q2 		$407K Buy
13,604
+3,189
+31% +$78.7K 0.01% 472
2017
Q1 		$231K Buy
+10,415
New +$223K 0.01% 544
2015
Q3 		– Sell
-9,134
Closed -$487K – 723
2015
Q2 		$487K Buy
+9,134
New +$485K 0.02% 443

Other funds holding JUNO

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Zacks Investment Management's JUNO Position: Q3 2017 in Review

Zacks Investment Management sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2017, closing a stake of 13,604 shares — an estimated $407K sold.

Zacks Investment Management first reported a position in JUNO in Q2 2015 and held it in 3 quarters. The position peaked at $487K in Q2 2015. 210 funds tracked by Wall St. Rank hold JUNO as of Q3 2017.

  • Zacks Investment Management reported no remaining Juno Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Zacks Investment Management sold 13,604 Juno Therapeutics, Inc. shares in Q3 2017, an estimated $407K.
  • Zacks Investment Management first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 3 quarters.
  • Zacks Investment Management's Juno Therapeutics, Inc. position peaked at $487K in Q2 2015.
  • 210 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2017.

Based on Zacks Investment Management's 13F filing for Q3 2017, filed 14 Nov 2017.